Step 6 of 12: Commercial and Account Segmentation
- Jun 18
- 7 min read
Stop Calling Every Hospital a Prospect. They're Not.
One of the fastest ways to waste a year after FDA clearance is convincing yourself every hospital is a prospect. They're not.
Some hospitals move quickly. Some move slowly. Some have physician champions who can push a new technology through procurement in a matter of months. Others have enough internal politics to turn a simple pilot into a multi-quarter project.
And yet one of the most common mistakes I see in early-stage MedTech is treating every hospital like a viable near-term opportunity.
The U.S. has more than 6,000 hospitals. A meaningful percentage will never be early adopters of anything. Another chunk aren't ready for your specific solution, even if they think they are. And some will take so long to close that the opportunity cost of chasing them in year one is far higher than most founders realize.
But because someone took a meeting, they end up in the pipeline.
Then leadership starts forecasting around them.
Then everyone acts surprised six months later when nothing has happened.
Segmentation exists to prevent that.
This is Step 6 of the recovery program. And if your current targeting strategy is "we'll talk to anyone who seems interested," this post may feel a little uncomfortable.
Good.
What Segmentation Actually Is
Segmentation is not sorting hospitals into small, medium, and large categories and pretending you've built a commercial strategy.
It's answering four questions honestly:
Which customers are most likely to adopt first?
Which customers matter strategically, even if they're slower?
Which customers should wait until we've built traction?
Which customers generate credibility versus revenue, and do we understand the difference?
Those are not the same question.
The accounts you pursue immediately after FDA clearance should look different from the accounts you pursue two years later. Your lighthouse accounts should look different from your scale accounts. Your scale accounts should look different from the large IDNs you eventually want to land.
The mistake most companies make is treating segmentation like a one-time exercise.
It isn't.
It's a living framework that should evolve every time the market teaches you something new.
The Four Types of Accounts Worth Understanding
Not every account deserves the same level of attention.
More importantly, not every account serves the same purpose.
Early Adopters
These are the accounts everyone wants.
Innovation-friendly environment. Clear operational pain. A physician champion with actual influence. Short approval cycles. A willingness to move before everyone else.
The problem is that true early adopters are much rarer than founders think.
Some physicians are excellent at looking like early adopters right up until the moment they need to do something.
They're enthusiastic in meetings. They love the technology. They want demos. They introduce you to colleagues.
Then the pilot paperwork shows up and they suddenly become impossible to find.
Others want to be associated with innovation more than they want to help implement it. They'll happily join an advisory board, attend conferences, and put their name next to your company. But when it comes time to generate data, support a pilot, or advocate internally, there's not much there.
Do your homework.
Talk to people who have worked with them before.
Enthusiasm and execution are two very different things.
Influencers
These are your academic centers, referral centers, and high-volume institutions.
They don't always generate the fastest revenue.
What they generate is credibility.
And credibility tends to create revenue later.
Healthcare adoption is heavily influenced by peer behavior. Whether people like admitting it or not, community hospitals often look to respected academic centers before deciding whether a technology deserves their attention.
That's why these accounts matter.
But don't assume every influential institution automatically creates influence.
I've seen companies spend nine months chasing prestigious accounts that produced zero revenue, zero publications, zero advocacy, and zero downstream momentum.
The logo looked fantastic on the investor deck.
The commercial impact was nonexistent.
Prestige and value are not interchangeable.
Scalers
These are the accounts that rarely move first but often move efficiently once someone else has gone first.
Community hospitals.
Regional systems.
Organizations that want evidence before making a decision.
This is where a lot of commercial scale actually comes from.
Ironically, founders often spend most of their energy chasing the flashy accounts while the future revenue base is sitting quietly in the background waiting for proof.
Strategics
These are the large IDNs and enterprise health systems everyone dreams about landing.
Massive contract potential.
Multi-site deployment opportunities.
Significant long-term value.
Also enormous complexity.
Multiple stakeholders. Lengthy procurement cycles. Extensive IT reviews. Budget committees. Legal reviews. More meetings than any reasonable person would voluntarily attend.
These opportunities matter.
They're just usually not first.
Unless the relationship was already warm before launch, most strategic accounts belong later in the sequence.
Not because they're bad opportunities.
Because timing matters.
Champion vs. Advocate: The Distinction That Saves Months
This gets overlooked constantly.
A champion loves your product.
An advocate can actually get it approved.
Those are not always the same person.
One of the most expensive mistakes founders make is confusing clinical enthusiasm with organizational influence.
A physician can genuinely believe in your technology and still have almost no influence over procurement, budgeting, supply chain, or value analysis.
Before you classify an account as a real opportunity, ask yourself:
Does this person have political capital inside the organization?
Can they influence spending decisions?
Will they advocate when we're not in the room?
Have they successfully helped introduce new technology before?
If the answer is mostly "I'm not sure," you don't have an advocate yet.
You have a fan.
Fans are nice.
Advocates close deals.
The Most Dangerous Account in Your Pipeline
It's usually the one you're most excited about.
The nationally recognized physician.
The famous academic center.
The institution everybody knows.
The meeting goes great.
The demo goes great.
Everyone leaves convinced momentum is building.
Then reality shows up.
IT wants a 90-day review.
The VAC doesn't meet until next quarter.
Supply chain wants additional economic analysis.
Budget planning begins.
Your champion gets pulled into another initiative.
Six months later you're still discussing a pilot.
Meanwhile, three regional hospitals nobody was excited about have already launched.
Founders confuse prestige with readiness all the time.
They are completely different variables.
One makes your investor deck look better.
The other generates revenue.
What Data Should Actually Drive Segmentation?
Segmentation shouldn't be based on who seemed interested at a conference.
It shouldn't be based on who took a meeting.
And it definitely shouldn't be based on who told you they "love what you're doing."
Healthcare professionals are generally polite. If you mistake politeness for buying intent, you're going to end up with a very healthy-looking pipeline and a very unhealthy revenue forecast.
Use actual data.
Things like:
Procedure volume
Hospital quality metrics
Existing technology adoption patterns
Competitor footprint
Referral network influence
Historical purchasing behavior
Physician reputation within the specialty
Existing relationships with your team or advisors
The best commercial teams combine objective data with field intelligence.
Because procedure volume matters.
But so does knowing the hospital you're targeting has a reputation for taking eighteen months to approve a stapler.
One tells you the size of the opportunity.
The other tells you whether you'll still be talking about that opportunity next fiscal year.
You need both.
The spreadsheet tells you what's possible.
The field tells you what's probable.
Ignore either one and you're making decisions with half the information.
Building a Segmentation Framework That Doesn't Fall Apart
Keep it simple.
One of the mistakes I see all the time is founders building incredibly sophisticated account scoring models with twenty-seven variables, three weighting systems, and enough formulas to qualify as a graduate statistics project.
Then nobody uses it.
A segmentation framework only works if people actually follow it.
Start with a handful of factors that genuinely matter:
Clinical fit
Champion quality
Organizational readiness
Revenue potential
Strategic value
Probability of adoption
That's enough to start.
Score accounts consistently.
Review the framework regularly.
And be willing to change it when the market proves you wrong.
Because it will.
The physician you were convinced would become your biggest advocate won't.
The account that looked perfect on paper will stall for reasons nobody could have predicted.
The regional hospital you almost ignored will become one of your best customers.
That's normal.
Good segmentation isn't about predicting the future perfectly.
It's about making better decisions than you would have made otherwise.
The goal isn't perfection.
The goal is reducing the number of expensive mistakes.
The Bottom Line
The U.S. hospital market is not a giant list of accounts waiting patiently for your sales team to call them.
It's political. It's hierarchical. It's budget-driven. And it's heavily influenced by factors that don't show up in most CRM fields.
The companies that understand this move faster.
They spend less time chasing the wrong opportunities, less time explaining stalled deals, and less time wondering why a pipeline full of "interested accounts" somehow isn't generating revenue.
The companies that ignore it usually end up with the opposite:
A pipeline that looks healthy and converts poorly.
Champions who can't actually influence a decision.
Academic center opportunities that are still "making progress" nine months later.
Forecasts built on optimism instead of evidence.
Segmentation isn't about finding every possible customer.
It's about finding the right customer at the right stage for the right reason.
Know which accounts are there to generate credibility.
Know which accounts are there to generate revenue.
Know the difference between a fan and an advocate.
And understand that the account you're most excited about is often not the account most likely to close.
One final thought.
Your segmentation model is going to be wrong.
Not completely wrong. Just wrong enough to matter.
The market always knows something you don't.
The best commercial teams don't build a segmentation model and fall in love with it. They build one, test it, challenge it, and update it every time reality teaches them something new.
Be disciplined enough to build the framework.
Be honest enough to change it.
Because the market doesn't care what your spreadsheet says.
And eventually, it always gets the final vote.
Next week: Step 7 - Marketing, Positioning, and Demand Generation
The part where we talk about why innovation doesn't speak for itself, why most MedTech messaging sounds exactly the same, and why your website is probably doing a better job helping your competitors than it is helping you.
Want to know where your GTM infrastructure actually stands?
👉 Take the U.S. Commercial Readiness Self-Assessment to see how prepared you are.
Curious about the other 11 steps to recovering your medtech business? Click here to learn more!
About the author
Robert Law is the founder of Metamorph MedTech, a go-to-market consulting practice built for medical device and healthcare AI companies that have cleared the FDA and now have to figure out what comes next. With a Kellogg MBA and hands-on experience across surgical robotics, implantable devices, and AI-powered platforms, Robert works in the space where great technology meets commercial reality: health economics, hospital sales strategy, VAC navigation, reimbursement positioning, and the kind of go-to-market infrastructure that turns pilots into revenue. He started Metamorph because too many good technologies were losing to bad commercial strategies, and that bothered him more than he could ignore. Learn more here.
Comments